In a phase 2 crossover trial in hereditary angioedema (74 randomised; 147 attacks in 62 analysed), oral deucrictibant 10, 20 or 30 mg reduced attack severity (VAS-3) at 4 h vs placebo (differences -16.75, -15.02, -16.28), with no grade ≥3 adverse events.
RCTn = 74
Maurer et al. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial